Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

NKTX

+ Watchlist+ Portfolio

Nkarta, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.25
52-Week Range
$1.11 – $3.72
Market Cap
$82.37M
P/E (TTM)
—
EPS (TTM)
-1.73
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.38
PEG Ratio
—
Return on Equity
-46.58%
Return on Assets
-22.48%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
5.79
Debt/Equity
0.33
Total Debt
$72.04M
Free Cash Flow
$-59.32M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$-2.11M

Market Snapshot

About

Nkarta, Inc. is a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies for cancer treatment. The company focuses on creating allogeneic, off-the-shelf NK cell therapies using its proprietary cellular engineering platform.